S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

OPKO Health Stock Forecast, Price & News

+0.08 (+1.81 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $4.50
50-Day Range
MA: $4.99
52-Week Range
Now: $4.50
Volume6.62 million shs
Average Volume8.69 million shs
Market Capitalization$3.02 billion
P/E RatioN/A
Dividend YieldN/A
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
OPKO Health logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OPK
Year FoundedN/A



Sales & Book Value

Annual Sales$901.90 million
Book Value$2.43 per share


Net Income$-314,920,000.00


Market Cap$3.02 billion
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.91 out of 5 stars

Medical Sector

93rd out of 1,962 stocks

Pharmaceutical Preparations Industry

38th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
+0.08 (+1.81 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

OPKO Health (NASDAQ:OPK) Frequently Asked Questions

Is OPKO Health a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPKO Health stock.
View analyst ratings for OPKO Health
or view top-rated stocks.

What stocks does MarketBeat like better than OPKO Health?

Wall Street analysts have given OPKO Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OPKO Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OPKO Health's next earnings date?

OPKO Health is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for OPKO Health

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) announced its quarterly earnings data on Thursday, February, 18th. The biotechnology company reported $0.05 EPS for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.01. OPKO Health had a negative trailing twelve-month return on equity of 2.61% and a negative net margin of 9.79%.
View OPKO Health's earnings history

How has OPKO Health's stock price been impacted by COVID-19?

OPKO Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPK shares have increased by 166.3% and is now trading at $4.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OPK?

2 equities research analysts have issued 12 month target prices for OPKO Health's stock. Their forecasts range from $8.00 to $10.00. On average, they expect OPKO Health's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts' price targets for OPKO Health
or view top-rated stocks among Wall Street analysts.

Who are OPKO Health's key executives?

OPKO Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 85, Pay $971.2k)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & Chief Technical Officer (Age 74, Pay $911.2k)
  • Mr. Adam E. Logal, Sr. VP & CFO (Age 43, Pay $611.2k)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 61, Pay $821.2k)
  • Mr. Rulfo Fernando Hernandez, Chief Accounting Officer, Treasurer & Global Corp. Controller (Age 42)
  • Dr. Arie Gutman, Pres of API (Age 67)
  • Mr. James DeMarco, Sr. VP of Pharmaceutical Sales
  • Mr. Thomas Nusbickel, Chief Commercial Officer
  • Dr. Akhtar Ashfaq, Sr. VP of Clinical R&D and Medical Affairs
  • Dr. Jon R. Cohen, Sr. VP & Director (Age 66)

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health CEO Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among OPKO Health's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OPKO Health's key competitors?

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.62%), Northern Trust Corp (1.12%), Dimensional Fund Advisors LP (0.84%), Charles Schwab Investment Management Inc. (0.53%), Nuveen Asset Management LLC (0.48%) and Bank of New York Mellon Corp (0.28%). Company insiders that own OPKO Health stock include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin.
View institutional ownership trends for OPKO Health

Which institutional investors are selling OPKO Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Morgan Stanley, Nuveen Asset Management LLC, Credit Suisse AG, Northern Trust Corp, GSA Capital Partners LLP, Engineers Gate Manager LP, and Bank of New York Mellon Corp.
View insider buying and selling activity for OPKO Health
or view top insider-selling stocks.

Which institutional investors are buying OPKO Health stock?

OPK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nordea Investment Management AB, First Trust Advisors LP, Renaissance Technologies LLC, Wells Fargo & Company MN, Dimensional Fund Advisors LP, State of New Jersey Common Pension Fund D, and Landscape Capital Management L.L.C.. Company insiders that have bought OPKO Health stock in the last two years include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel, and Steven D Rubin.
View insider buying and selling activity for OPKO Health
or or view top insider-buying stocks.

How do I buy shares of OPKO Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $4.50.

How much money does OPKO Health make?

OPKO Health has a market capitalization of $3.02 billion and generates $901.90 million in revenue each year. The biotechnology company earns $-314,920,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does OPKO Health have?

OPKO Health employs 6,096 workers across the globe.

What is OPKO Health's official website?

The official website for OPKO Health is www.opko.com.

Where are OPKO Health's headquarters?

OPKO Health is headquartered at 4400 BISCAYNE BLVD., MIAMI FL, 33137.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.